Dementia News & Events

US College of Physicians and the Academy of Family Physicians Issue New Guidelines on Drugs to Treat Dementia

The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) issued a new guideline on current pharmacologic treatment of dementia. The guideline appears in the March 4, 2008 issue of Annals of Internal Medicine, which is available online at http://www.annals.org

According to their press release:
(for full press release, please visit: http://www.acponline.org/pressroom/dementia.htm# )

"A committee representing ACP and AAFP reviewed dementia literature for outcomes such as cognition, global function, behaviour/ mood, and quality of life/ activities of daily living -- areas of importance to physicians treating patients. The committee found that high-quality scientific evidence was limited and so developed cautious recommendations:

1. Clinicians should base the decision to try therapy with the FDA approved drugs for dementia on an individualized assessment of the patient.

2. Clinicians should base the choice of drugs on tolerability, adverse effect profile, ease of use and cost of medication.

3. Further research is urgently needed to address gaps in knowledge about the clinical effectiveness of pharmacologic management of dementia."

Currently five drugs are approved by the FDA for dementia: four acetylcholinesterase inhibitors [donepezil (Aricept ®, galantamine (Razadyne ^TM, Reminyl ^TM, Nivalin), rivastigmine (Exelon), and tacrine], and one neuropeptide-modifying agent [memantine (Namenda®]. These drugs do not cure dementia (there is no cure at this time) or repair brain damage. They may improve symptoms or slow down the disease.

"Doctors, patients, and family care-givers desperately want information on how to treat this disease," said Amir Qaseem, MD, PhD, MHA, Senior Medical Associate in the Clinical Programs and Quality of Care Department at ACP. "It is disheartening to find out that all we  have to work with is these five drugs, and the evidence on these is scant. Consider that in 50 years, one in 45 Americans will suffer from Alzheimer's disease. This is a huge problem."

The guideline outlines research that needs to be done:

-Evaluate the appropriate duration of therapy.
-Test drugs head-to-head.
-Test drugs in combination therapy.

One reason for the urgent call for research is the deficiencies found in the existing medical literature.

The ACP-AAFP committee found that most of the existing studies focused on statistical significance of changes, but patients with dementia, caregivers, and physicians are more interested in clinically important improvement.

"More research is warranted because the available evidence concerning these pharmaceuticals' effects on quality of life is mixed and the clinical significance of many of the findings is questionable," said Kenneth G. Schellhase, MD, MPH, and AAFP representative on the guideline committee. "In addition, the duration of existing trials was usually less than one  year, providing insufficient information to determine the optimal length of treatment, and few trials compare one drug directly with another."

In summary, no convincing evidence demonstrated that one therapeutic treatment is more effective than another, the committee concluded.

The National Institutes of Health describes dementia as a group of symptoms caused by disorders that affect the brain. Dementia is not a specific disease. NIH says "people with dementia may not be able to think well enough to do normal activities, such as getting dressed or eating. They may lose their ability to solve problems or control their emotions. Their personalities may change. They may become agitated or see things that are not there."